chronic myeloid leukaemia

News

Update: Rumour confirmed as MSD buys Terns for $6.7bn

MSD's glut of pipeline-boosting deals in the build-up to a looming patent cliff has continued with a $6.7bn bid to acquire Terns Pharma.

Oncology

Targeting blood cancers with high unmet need

When it comes to myeloid malignancies such as acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), treatment progress has been slow.

Oncology

pharmaphorum podcast Episode 205a - Amy Burroughs, Terns Pharmaceuticals

Doing good in people’s lives: Amy Burroughs discusses CML

Amy Burroughs, CEO, Terns Pharmaceuticals, discusses available treatments for CML, the potential of allosteric TKIs, and the wider oncology landscape.

News

Novartis gets FDA okay for frontline use of Scemblix in CML

Novartis has picked up a new FDA approval for its chronic myeloid leukaemia therapy Scemblix that it believes is critical to unlocking the drug's blockbuster sales potential.

News